Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 292-429-7 | CAS number: 90622-29-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Toxicity to reproduction
Administrative data
- Endpoint:
- toxicity to reproduction
- Remarks:
- other: OECD 408 with additional histopathological assessment of the reproductive organs
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 01 Jul 2014 to 20 Apr 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was performed according to an established protocol and consistent with Good Laboratory Practice.
Cross-reference
- Reason / purpose for cross-reference:
- reference to same study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- other: OECD 408 with additional histopathological assessment of the reproductive organs
- GLP compliance:
- yes
Test material
- Reference substance name:
- Alkenes, C13-14, hydroformylation products, distn. residues
- EC Number:
- 292-429-7
- EC Name:
- Alkenes, C13-14, hydroformylation products, distn. residues
- Cas Number:
- 90622-29-0
- Molecular formula:
- not applicable; UVCB
- IUPAC Name:
- Alkenes, C13-14, hydroformylation products, distn. residues
- Test material form:
- liquid
- Details on test material:
- - Name of test material (as cited in study report): ALCHISOR CAL 145
- Substance type: Product
- Physical state: liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Test animals: The Han Wistar rat was chosen as the animal model for this study as it is an accepted rodent species for preclinical toxicity testing by regulatory agencies. On 10 Jun 2014, 52 male and 52 female Han Wistar rats were received from Charles River UK, Margate, Kent. At the initiation of dosing the animals were 8-9 weeks old and weighed between 212-300 g (males) and 147-194 g (females). The total number of animals used in this study was considered to be the minimum required to properly characterise the effects of the test item. This study was designed such that it did not require an unnecessary number of animals to accomplish its objectives.Environmental conditions: Temperatures of 18-24°C with a relative humidity of 40-75% were maintained. The target temperature and humidity ranges were 19-23oC and 40-70% respectively. A 12 hour light/12 hour dark cycle and ten or greater air changes per hour with 100% fresh air (no air recirculation) were maintained in the animal rooms.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% HPMC (Methocel E4M), 0.1% Tween 80 in Milli-Q water
- Details on exposure:
- The test and control items were administered to the appropriate animals by once daily oral gavage for 90 days. The dose volume for each animal was based on the most recent body weight measurement. The doses were given using a syringe with attached gavage cannula. The first day of dosing was designated as Day 1.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Test item dosing formulations were prepared, based on a method established at the Test Facility (under Study Numbers 432356 and 431130), at appropriate concentrations to meet dosage level requirements. The required amount of test item was weighed and transferred to a pre-labelled container. The appropriate amount of vehicle (control item) was weighed and added to the container and the solution was stirred magnetically until a visibly homogeneous formulation was obtained.The dosing formulations were prepared weekly stored in a refrigerator set to maintain 2-8C, and dispensed daily. The dosing formulations were stirred continuously during dosing. Any residual volumes were discarded. Details of the preparation and dispensing of the test item have been retained in the Study Records.Dose formulation samples were collected for analysis during Week 1, 6 and 12, and were submitted for analysis within 1 week of preparation. All samples to be analysed were transferred in ambient conditions to the analytical laboratory at the Test Facility. Analyses were performed using a validated analytical procedure (AP No. 432356). Duplicate top, middle and bottom (middle only for Group 1, concentration only) samples(1 mL) for each sampling time point were sent to the analytical laboratory at the Test Facility. Triplicate top, middle and bottom samples were retained as backup samples. Concentration results were considered acceptable if mean sample concentration results were within or equal to ± 10% of theoretical concentration. Each individual sample concentration result within or equal to ± 20%. For homogeneity, the criteria for acceptability was a relative standard deviation (RSD) of concentrations of <= 10% for each group.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- Once daily oral gavage
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0 mg/mL
Basis:
nominal in water
- Remarks:
- Doses / Concentrations:
10 mg/mL
Basis:
nominal in water
- Remarks:
- Doses / Concentrations:
30 mg/mL
Basis:
nominal in water
- Remarks:
- Doses / Concentrations:
100 mg/mL
Basis:
nominal in water
- No. of animals per sex per dose:
- 10 animals per sex per dose group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- The objective of this study was to determine the potential toxicity of Alkenes, C13-C14, hydroformylation products, distn. residues (CAS/No. 90622-29-0) when given by oral gavage for at least 90 days to rats and to evaluate the potential reversibility of any findings after 28 days.Alkenes, C13-C14, hydroformylation products, distn residues (CAS/No. 90622-29-0) was administered using 0.5% HPMC (Methocel E4M), 0.1% Tween 80 in Milli-Q water as the vehicle at a constant dose volume of 10 mL/kg. Dose levels were 0 (control), 20, 30, and 100 mg/mL (corresponding to dosage levels of 0, 100, 300, and 1000 mg/kg/day, respectively). Five males and five females at each of the control and high-dose levels, a total of 20 animals, were designated as recovery animals. Additional histopathological examination of reproductive organs and related tissues was performed in order to address the reproductive toxicity endpoint.
Examinations
- Parental animals: Observations and examinations:
- All animals were checked twice daily, once in the morning and once in the afternoon throughout the study for general health/mortality and moribundity. All animals were removed from their cages for examination once a week from Week -2 and on the first day of scheduled necropsy. All animals were observed regularly throughout the day on dosing days, with particular attention paid during and for the first hour after dosing and at least once daily on non-dosing days during the dosing period for reaction to treatment. In addition animals were observed at least once daily during the recovery period. The onset, intensity and duration of any signs were recorded. Body weights were recorded for each animal twice during pretreatment, daily during the dosing period and twice weekly during the recovery period.Animals were individually weighed. A weight was recorded on the first day of scheduled necropsy.Food consumption was quantitatively measured twice during pretreatment and as follows during the dosing period: Weekly in Weeks 1 to 12 and over 6 days in Week 13 for main study animals: the first 5 animals per sex in Group 1 and all animals in Groups 2 and 3; Weekly in Weeks 1-13 and over 3 days in Week 14 for main study animals: the last 5 animals per sex in Group 1, all animals in Group 3 and all recovery study animals. Food consumption was measured weekly during the recovery period.Water consumption was monitored throughout the study by visual inspection of the water bottles.All animals were subject to an ophthalmic examination once during pretreatment, Control and High Dose animals were examined in Week 13, and all recovery animals were examined during Week 16 and Week 18.Detailed functional observations (cageside observations, observations in a standardized arena; functional tests; grip strength; pain perception; landing food splay; and motor activity) were performed for all animals once during pretreatment period, once during Week 12 of the dosing period and once for all recovery animals during Week 18.
- Postmortem examinations (parental animals):
- All animals were weighed, and euthanised by exposure to a rising concentration of carbon dioxide, followed by exsanguination. The animals were euthanised rotating across dose groups such that similar numbers of animals from each group, including controls were necropsied at similar times throughout the day. Animals were not fasted before their scheduled necropsy.All main study and recovery animals were subjected to a complete necropsy examination, which included evaluation of the carcass and musculoskeletal system; all external surfaces and orifices; cranial cavity and external surfaces of the brain; and thoracic, abdominal, and pelvic cavities with their associated organs and tissues. Scheduled necropsy examinations were conducted under the supervision of a veterinarian with appropriate training and experience in animal anatomy and gross pathology. See the following summary for additional pathology measures.
Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
- Clinical signs:
- no effects observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- no effects observed
- Other effects:
- no effects observed
Reproductive function / performance (P0)
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- not specified
- Reproductive performance:
- not specified
Details on results (P0)
Administration of Alkenes, C13-C14, hydroformylation products, distn. residues (CAS/No. 90622-29-0) by once daily oral gavage was well tolerated in rats at levels of 100, 300 and 1000 mg/kg/day. Based on the results, due to reversible changes in the liver weights in males and females the no-observed-adverse-effect level (NOAEL) was considered to be 1000 mg/kg/day.
Effect levels (P0)
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Results: P1 (second parental generation)
General toxicity (P1)
- Clinical signs:
- no effects observed
Effect levels (P1)
- Key result
- Remarks on result:
- not measured/tested
Results: F1 generation
General toxicity (F1)
- Clinical signs:
- not examined
- Mortality / viability:
- not specified
- Body weight and weight changes:
- not specified
- Sexual maturation:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Histopathological findings:
- not specified
Effect levels (F1)
- Key result
- Remarks on result:
- not measured/tested
Results: F2 generation
General toxicity (F2)
- Clinical signs:
- not examined
Overall reproductive toxicity
- Key result
- Reproductive effects observed:
- not specified
Any other information on results incl. tables
RESULTS Histopathology of Reproductive Organs and Tissues Terminal and Recovery Euthanasia (Day 91/95/96 and 123) Oral (gavage) administration of Alkenes, C13-C14, hydroformylation products, distn. residues (CAS/No. 90622-29-0) once a day to rats for up to 90 days at doses of 0, 100, 300, or 1000 mg/kg/day resulted in no early decedents by the end of the dosing period. In support of the addressing questions of the potential for reproductive toxicity, gross pathology and histopathology results are summarized in the tables below for reproductive organs and tissues of select test animals. At the end of the treatment period, no test article-related gross or microscopic findings were noted. The microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of rat, and/or were of similar incidence and severity in control and treated animals and, therefore, were considered unrelated to administration of Alkenes, C13-C14, hydroformylation products, distn. residues.
Summary of Gross Pathology Findings (Day 91/95/96)
Removal Reason: TERMINAL EUTHANASIA | Male | Female | ||||||
0 | 100 | 300 | 1000 | 0 | 100 | 300 | 1000 | |
mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | |
Group 1 | Group 2 | Group 3 | Group 4 | Group 1 | Group 2 | Group 3 | Group 4 | |
Number of animals: | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
UTERUS | ||||||||
- Submitted | - | - | - | - | 10 | 1 | 2 | 10 |
- No Visible Lesions | - | - | - | - | 7 | 0 | 0 | 10 |
- Dilatation; clear | - | - | - | - | 3 | 1 | 2 | 0 |
Summary of Gross Pathology Findings (Day 123)
|
Summary of Histopathology Findings (Day 91/95/96)
Removal Reason: TERMINAL EUTHANASIA | Male | Female | ||||||
0 | 100 | 300 | 1000 | 0 | 100 | 300 | 1000 | |
mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | |
Group 1 | Group 2 | Group 3 | Group 4 | Group 1 | Group 2 | Group 3 | Group 4 | |
Number of animals: | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
CERVIX | ||||||||
-Examined | - | - | - | - | 10 | 0 | 0 | 10 |
- No Visible Lesions | - | - | - | - | 10 | - | - | 10 |
EPIDIDYMIS | ||||||||
- Examined | 10 | 0 | 0 | 10 | - | - | - | - |
- No Visible Lesions | 10 | - | - | 10 | - | - | - | - |
GLAND, MAMMARY | ||||||||
- Examined | 10 | 0 | 0 | 10 | 10 | 0 | 0 | 10 |
- No Visible Lesions | 10 | - | - | 10 | 10 | - | - | 10 |
GLAND, PROSTATE | ||||||||
- Examined | 10 | 0 | 0 | 10 | - | - | - | - |
- No Visible Lesions | 8 | - | - | 10 | - | - | - | - |
- Infiltration, mononuclear cell | 2 | - | - | 0 | - | - | - | - |
- ....mild | 2 | - | - | 0 | - | - | - | - |
GLAND, SEMINAL VESICLE | ||||||||
- Examined | 10 | 0 | 0 | 10 | - | - | - | - |
- No Visible Lesions | 10 | - | - | 10 | - | - | - | - |
OVARY | ||||||||
- Examined | - | - | - | - | 10 | 0 | 0 | 10 |
- No Visible Lesions | - | - | - | - | 10 | - | - | 10 |
OVIDUCT | ||||||||
- Examined | - | - | - | - | 10 | 0 | 0 | 10 |
- No Visible Lesions | - | - | - | - | 10 | - | - | 10 |
TESTIS | ||||||||
- Examined | 10 | 0 | 0 | 10 | - | - | - | - |
- No Visible Lesions | 10 | - | - | 10 | - | - | - | - |
UTERUS | ||||||||
- Examined | - | - | - | - | 10 | 1 | 2 | 10 |
- No Visible Lesions | - | - | - | - | 10 | 1 | 2 | 10 |
VAGINA | ||||||||
- Examined | - | - | - | - | 9 | 0 | 0 | 10 |
- No Visible Lesions | - | - | - | - | 9 | - | - | 10 |
- Not Examined: Not Present in Section | - | - | - | - | 1 | 0 | 0 | 0 |
Summary of Histopathology Findings (Day 123)
Removal Reason: RECOVERY EUTHANASIA | Male | Female | ||
0 | 1000 | 0 | 1000 | |
mg/kg/day | mg/kg/day | mg/kg/day | mg/kg/day | |
Group 1 | Group 4 | Group 1 | Group 4 | |
Number of animals: | 5 | 5 | 5 | 5 |
CERVIX | ||||
- Examined | - | - | 5 | 4 |
- No Visible Lesions | - | - | 5 | 4 |
- Not Prsent in Wet Tissues | - | - | 0 | 1 |
EPIDIDYMIS | ||||
- Examined | 5 | 5 | - | - |
- No Visible Lesions | 5 | 5 | - | - |
GLAND, MAMMARY | ||||
- Examined | 5 | 5 | 5 | 5 |
- No Visible Lesions | 5 | 5 | 5 | 5 |
GLAND, PROSTATE | ||||
- Examined | 5 | 5 | - | - |
- No Visible Lesions | 5 | 5 | - | - |
GLAND, SEMINAL VESICLE | ||||
- Examined | 5 | 5 | - | - |
- No Visible Lesions | 5 | 5 | - | - |
OVARY | ||||
- Examined | - | - | 5 | 5 |
- No Visible Lesions | - | - | 5 | 5 |
OVIDUCT | ||||
- Examined | - | - | 5 | 5 |
- No Visible Lesions | - | - | 5 | 5 |
TESTIS | ||||
- Examined | 5 | 5 | - | - |
- No Visible Lesions | 5 | 5 | - | - |
UTERUS | ||||
- Examined | - | - | 5 | 5 |
- No Visible Lesions | - | - | 5 | 5 |
VAGINA | ||||
- Examined | - | - | 5 | 5 |
- No Visible Lesions | - | - | 5 | 5 |
Applicant's summary and conclusion
- Conclusions:
- Regarding potential effects of the registered substance on reproductive tissues, no test article-related gross or microscopic findings were noted. The microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of rat, and/or were of similar incidence and severity in control and treated animals and, therefore, were considered unrelated to administration of Alkenes, C13-C14, hydroformylation products, distn. residues. Thus the NOEL for effects on reproductive tissues is considered to be 1000 mg/kg/day.
- Executive summary:
Oral (gavage) administration of Alkenes, C13-C14, hydroformylation products, distn. residues (CAS/No. 90622-29-0) once a day to rats for up to 90 days at doses of 0, 100, 300, or 1000 mg/kg/day resulted in no early decedents by the end of the dosing period. In support of the addressing questions of the potential for reproductive toxicity, gross pathology and histopathology results are summarized in the tables below for reproductive organs and tissues of select test animals. At the end of the treatment period, no test article-related gross or microscopic findings were noted. The microscopic findings observed were considered incidental, of the nature commonly observed in this strain and age of rat, and/or were of similar incidence and severity in control and treated animals and, therefore, were considered unrelated to administration of Alkenes, C13-C14, hydroformylation products, distn. residues. Thus the NOEL for effects on reproductive tissues is considered to be 1000 mg/kg/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.